Oncotelic Therapeutics Inc. has announced the launch of PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful insights from large-scale biomedical datasets without the need to train bespoke large language models. Alongside this, the company has opened access to its comprehensive TGF-β literature corpus, which includes more than 125,000 PubMed abstracts, via a dedicated Discord research channel. The PDAOAI platform has already supported research published in peer-reviewed journals, such as the International Journal of Molecular Sciences, where it aided in synthesizing evidence on survival-associated biological axes, including TGFB2, DNMT3A, and GMPS, across various tumor microenvironment settings and patient populations. Researchers are invited to join the community for further collaboration and data exploration.